Genmab — August 2020
-
BMS earnings slide 13 gives an idea of Revlimid and Pomalyst sales for comparison https://s21.q4cdn.com/104148044/files/doc_presentations/2020/BMY-Q22020-Earnings-Updates.pdf
-
Overall, the street is currently modeling roughl y $1.5 billion consensus estimates by 2026 from belantamab https://thenonconsensus.com/blog/2019/11/20/gsk-detailing-growth-opportunities-in-oncology-and-upcoming-bcma-data
-
God morgen.
-
Aflagt Genmab-middel sælger stort – milliarder kan være på vej i royalties
Det tidligere Genmab-middel Tepezza sælger langt bedre, end hvad den nuværende ejer Horizon Therapeutics turde håbe på. Da Genmab har ret til royalties, kan der være milliarder på vej til det danske biotekfirma.
(medwatch.dk)
-
-
Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A - PubMed
Tumor necrosis factor (TNF) and interleukin (IL)-17A are pleiotropic cytokines implicated in the pathogenesis of several autoimmune diseases including rheumatoid arthritis (RA) and psoriatic arthritis (PsA). JNJ-61178104 is a novel human anti-TNF and anti-IL-17A monovalent, bispecific antibody that …
PubMed (pubmed.ncbi.nlm.nih.gov)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind